Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2026-01-01 @ 7:22 PM
Study NCT ID:
NCT06898957
Status:
RECRUITING
Last Update Posted:
2025-12-05
First Post:
2025-03-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-16
Start Date Type:
ACTUAL
Primary Completion Date:
2031-04-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-04-23
Completion Date Type:
ESTIMATED
First Submit Date:
2025-03-21
First Submit QC Date:
None
Study First Post Date:
2025-03-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-03
Last Update Post Date:
2025-12-05
Last Update Post Date Type:
ESTIMATED